Explore our news and publications to discover groundbreaking research, innovative drug developments, and insightful analyses on aging and longevity. Follow our journey as we share updates and breakthroughs.
The Smart Grant will be used in a one-year project involving the company’s Anti-Necrotic™ technology, specifically around acute tubular necrosis (ATN), which is a leading cause of kidney dysfunction, degeneration and ageing.
Based at Babraham Research Campus, affiliated with the University of Cambridge, LinkGevity has been chosen for KQ Labs Programme delivered by the Francis Crick Institute. “Designed to propel world-class healthcare innovation, LinkGevity’s therapeutic data, innovative approach and scientific leadership secured its place in the cohort.”
LinkGevity receives investment via the prestigious KQ Labs Programme – delivered by the Francis Crick Institute, Europe’s largest biomedical research centre. Only 10 startups are chosen annually, after a rigorous due diligence process, for this highly selective initiative that is aimed at propelling world class healthcare innovations forward.
Stay informed about the latest seminars, talks, and other public communications of our groundbreaking research and discoveries.
